MorphoSys AG
https://www.morphosys.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MorphoSys AG
Keeping Track: Four Novel Agents Clear US FDA, Including Evrysdi, Blenrep
The latest US FDA approvals and actions from the Pink Sheet’s US FDA Performance Tracker.
Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Morphosys/Incyte’s Monjuvi Wins Early US FDA Approval In Second-Line DLBCL
Monjuvi’s good efficacy and safety profile should enable its broad adoption in the second line DLBCL space and help it compete well against rival CAR-T therapies, analysts said.
Hanmi, Bioapp Accelerate Plant-Derived Coronavirus Vaccine
Hanmi is accelerating development of a plant-derived COVID-19 vaccine with Bioapp after successful early, the forming part of the leading South Korean pharma group’s post-pandemic business vision, which includes 'green biotech'.
Company Information
- Industry
- Biotechnology
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Lanthio Pharma B.V.
- MorphoSys US Inc.
- Sloning BioTechnology